MIRA INFORM REPORT

 

 

Report Date :

18.10.2013

 

IDENTIFICATION DETAILS

 

Name :

DAEWOONG BIO INC.

 

 

Registered Office :

35-9, Jeyakgongdan 4-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea

 

 

Country :

South Korea

 

 

Financials (as on) :

31.12.2012

 

 

Date of Incorporation :

04.02.2009

 

 

Com. Reg. No.:

124-86-77584

 

 

Legal Form :

Co., Ltd by shares

 

 

Line of Business :

Manufacture of Medicinal Chemicals and Antibiotics

 

 

No. of Employees :

218

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

South Korea

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

SOUTH KOREA - ECONOMIC OVERVIEW

 

South Korea over the past four decades has demonstrated incredible growth and global integration to become a high-tech industrialized economy. In the 1960s, GDP per capita was comparable with levels in the poorer countries of Africa and Asia. In 2004, South Korea joined the trillion dollar club of world economies, and is currently the world's 12th largest economy. Initially, a system of close government and business ties, including directed credit and import restrictions, made this success possible. The government promoted the import of raw materials and technology at the expense of consumer goods, and encouraged savings and investment over consumption. The Asian financial crisis of 1997-98 exposed longstanding weaknesses in South Korea's development model including high debt/equity ratios and massive short-term foreign borrowing. GDP plunged by 6.9% in 1998, and then recovered by 9% in 1999-2000. Korea adopted numerous economic reforms following the crisis, including greater openness to foreign investment and imports. Growth moderated to about 4% annually between 2003 and 2007. Korea''s export focused economy was hit hard by the 2008 global economic downturn, but quickly rebounded in subsequent years, reaching 6.3% growth in 2010. The US-South Korea Free Trade Agreement was ratified by both governments in 2011 and went into effect in March 2012. Throughout 2012 the economy experienced sluggish growth because of market slowdowns in the United States, China, and the Eurozone. The incoming administration in 2013, following the December 2012 presidential election, is likely to face the challenges of balancing heavy reliance on exports with developing domestic-oriented sectors, such as services. The South Korean economy''s long term challenges include a rapidly aging population, inflexible labor market, and heavy reliance on exports - which comprise half of GDP.

Source : CIA

 

Basic Information

 

Basic

 

Company Name

DAEWOONG BIO INC.

Registered Address

906-5, Sangsin-ri, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea

(New Adress System : 35-9, Jeyakgongdan 4-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea)

Building

Hyangnam Pharmaceutical Industries Complex

Zip Code

445-922

Tel

+82-31-353-5271~3

Fax

+82-31-353-5626

E-mail

tony@daewoong.co.kr;dwle@daewoong.co.kr

Website

www.daewoongchemical.co.kr

Trading Address

Daewoong Pharmaceutical Bldg.,163-3, Samseong-dong, Gangnam-gu, Seoul, Korea

Tel

+82-2-550-8641

Fax

+82-2-550-8249

Type

Export/Import

Industry

Manufacture of Medicinal Chemicals and Antibiotics

  Main Business

Ursodeoxycholic Acid, Amoxicillin, Ceftriaxone Sodium, Coenzyme Q10, Cefodizime Sodium, Cefotiam Hydrochloride, Lansoprazole, Fluconazole

Established (mm/dd/yyyy)

04/02/2009

 

 

Detailed Products

 

Activity

Detailed Products (UNSPSC)

Sell

Drugs and Pharmaceutical Products(51000000)

Sell

Penicillin(51101507)

 

 

CEO’s

 

Name

Lee Jong-Wook

Address

Suite 117-603, 155, Seongbok-dong, Suji-gu, Yongin-si, Gyeonggi-do, Korea

Date of Birth

03/10/1949

Title

Co-President & CEO

Sex

Male

Nationality

Korean

 

 

Profiles

 

Capital (KRW)

1,000,000,000

Employees

218

Formation

Co., Ltd by shares

A Company of DAEWOONG GROUP

Bank Details

Woori Bank-Samsung Dong Branch

Shanhan Bank

Corporate Registered No.

134811-0172221

Business Registered No.

124-86-77584

Permit & Licenses

Int’l Trade No.: 45370498

Shareholder Position

Name

Shares

%

DAEWOONG CO., LTD.(131111-0000271)

200,000

100.00

TOTAL

200,000

100.00

Company History

04/02/2009 Incorporated as the present name after spinning off Raw Materials Business for Pharmaceuticals from DAEWOONG CHEMICAL CO., LTD.(131112-0004827) located at 906-5, Sangsin-ri, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea.

06/28/2010 Changed the financial closing date to December 31 from March 31

 

 

 

 

Detailed Information

 

Management

 

Job Description

Title

Name

Sex

Nationality

Inauguration Date

Co-President & CEO

Mr.

Lee Jong-Wook

Male

Korean

12/10/2009

Co-President & CEO

Mr.

Yoon Jae-Seung

Male

Korean

06/08/2009

Director

Mr.

Yoon Jae-Hoon

Male

Korean

04/02/2009

Director

Mr.

Yoon Jae--Choon

Male

Korean

04/02/2009

Director

Mr.

Seo Jong-Won

Male

Korean

06/28/2010

Director

Mr.

Jeon Woo-Bang

Male

Korean

03/15/2013

Auditor

Mr.

Lee Won-Keun

Male

Korean

03/30/2012

 

Financials

 

Year / Unit : KRW

Sales

Assets

Net Income

12/2012

138,013,847,692

172,367,811,294

10,707,557,663

12/2011

132,837,744,799

176,380,999,684

8,850,003,832

12/2010

91,698,215,718

135,023,006,082

7,507,357,320

03/2010

101,131,109,420

96,739,291,272

9,026,412,992

 

 

Financial Description

 

Authorized Capital(KRW)

5,000,000,000

Paid-Up Capital(KRW)

1,000,000,000

Total Issues Shares

200,000

 

Balance Sheet

Unit : Korean Won

As of 12/31/2012

As of 12/31/2011

As of 12/31/2010

Total Assets

172,367,811,294

176,380,999,684

135,023,006,082

Current Assets

71,286,545,088

73,521,775,239

47,860,274,957

Cash & Cash Equivalents

311,157,736

3,981,176,387

1,191,566,962

Trade Receivables & Other Receivables

34,289,905,447

39,645,313,853

25,523,337,878

Inventories

33,270,259,966

26,289,328,877

16,002,023,830

Other Current Assets

3,415,221,939

3,605,956,122

5,143,346,287

Non-Current Assets

101,081,266,206

102,859,224,445

87,162,731,125

Marketable Financial Instruments

119,945,000

119,945,000

546,555,000

Long-Term Trade Receivables & Other Receivables

477,247,062

472,896,062

87,927,062

Investment_Subsidiaries

6,911,113,868

4,026,762,100

3,349,614,050

Investment_Related Companies

635,571,078

1,271,142,157

1,271,142,157

Tangibles

82,458,896,926

87,178,321,231

72,338,965,267

Investment_Real Estates

6,557,161,392

6,612,478,819

6,667,796,246

Intangibles

2,345,818,848

2,600,448,072

2,653,077,232

Deferred Income Tax Assets

1,575,512,032

577,231,004

247,654,111

Total Liabilities

72,491,417,315

87,086,267,064

54,720,916,387

Current Liabilities

66,687,422,294

74,315,425,967

38,992,544,582

Trade Payables & Other Payables

22,301,193,691

35,057,398,224

26,431,590,430

Short-Term Borrowings

42,674,772,953

29,498,365,511

10,365,183,746

Current Portion of Long-Term Borrowings

-

9,000,000,000

-

Deferred Income Tax Assets

1,203,829,355

156,595,182

1,670,652,506

Other Current Liabilities

507,626,295

603,067,050

525,117,900

Non-Current Liabilities

5,803,995,021

12,770,841,097

15,728,371,805

Long-Term Trade Payables & Other Payables

3,000,000,000

3,000,000,000

3,000,000,000

Long-Term Borrowings

1,700,000,000

9,000,000,000

12,000,000,000

Provision for Severance & Retirement

1,103,995,021

770,841,097

728,371,805

Capital Stock

1,000,000,000

1,000,000,000

1,000,000,000

Capital Surplus

63,373,795,312

63,373,795,312

63,373,795,312

Profit Surplus

35,502,598,667

24,920,937,308

15,928,294,383

Total Equity

99,876,393,979

89,294,732,620

80,302,089,695

Liab. & Shareholder’s Equity

172,367,811,294

176,380,999,684

135,023,006,082

 

Income Statement

Unit : Korean Won

As of 12/31/2012

As of 12/31/2011

As of 12/31/2010

Revenues

138,013,847,692

132,837,744,799

91,698,215,718

Operating Expenses

-104,084,325,535

-107,845,972,478

81,492,191,494

Cost of Sold Goods

33,929,522,157

24,991,772,321

73,108,260,712

Selling & Admin. Expenses

-21,405,436,741

-14,227,284,715

8,247,162,457

R&D

12,524,085,416

10,764,487,606

136,768,325

Other Operating Income

-1,037,590,012

-716,128,890

-165,614,329

Operating Income

-1,581,406,630

-733,292,857

10,040,409,895

Finance Income

543,816,618

17,163,967

32,483,204

Income Before Taxes

11,486,495,404

10,048,358,716

10,072,893,099

Income Before Taxes

778,937,741

1,198,354,884

2,565,535,779

Net Income

10,707,557,663

8,850,003,832

7,507,357,320

 

Cash Flows

Unit : Korean Won

As of 12/31/2012

As of 12/31/2011

As of 12/31/2010

Operating Activities Cash Flows

3,324,688,444

564,334,495

11,126,406,309

Cash Flows from Operating

5,631,207,885

4,268,108,346

13,114,632,970

Net Income

10,707,557,663

8,850,003,832

7,507,357,320

Adjustment

10,922,980,699

8,691,730,498

5,353,179,793

Changes in Asset/ & Liability

-15,999,330,477

-13,273,625,984

254,095,857

Interests Received

123,715,867

90,322,543

203,803,817

Interests Paid

-1,735,759,926

-711,875,754

-32,806,703

Income Taxes

-694,475,382

-3,082,220,640

-2,159,223,775

Cash Flows from Investing

-4,774,213,298

-22,173,037,835

-34,613,815,069

Cash Flows from Financing

-2,220,484,558

24,398,312,765

20,442,967,358

Increase/Decrease in Cash

-3,670,009,412

2,789,609,425

-3,044,441,402

Cash at the Beginning of Year

3,981,176,387

1,191,566,962

4,240,597,493

Cash at the End of Year

311,157,736

3,981,176,387

1,191,566,962

 

 

Products, Technologies, Services Description

 

Main Products & Services

Ursodeoxycholic Acid, Amoxicillin, Ceftriaxone Sodium, Coenzyme Q10, Cefodizime Sodium, Cefotiam Hydrochloride, Lansoprazole, Fluconazole

Detailed Products Spec.

 

Technologies Acquired

 

 

 

Trade Partners & Competitors

 

Suppliers

 

Customers

 

Competitors

YUHAN CORPORATION

49-6, DAEBANG-DONG, DONGJAK-GU, SEOUL, KOREA

TEL:+82-2-828-0181  FAX:+82-2-828-0300

 

KUNWHA PHARMACEUTICAL CO., LTD.

94, GARAKBON-DONG, SONGPA-GU, SEOUL, KOREA

TEL:+82-2-2047-7700  FAX:+82-2-430-1135

 

YUHAN CHEMICAL INC.

5BA-402, SIHWA INDUSTRIAL COMPLEX, 678-1, SEONGGOK-DONG, DANWON-GU, ANSAN-SI, GYEONGGI-DO, KOREA

TEL:+82-31-488-5800  FAX:+82-31-499-4115

 

 

Related Parties (Subsidiaries, Joint-Venture & Affiliates)

 

Affiliates

DAEWOONG CO., LTD.(110111-2857146)

DAEWOONG INTERNATIONAL CORP.(110111-0742985)

R&P KOREA CO., LTD.(110111-0358021)

DAEWOONG MANEGEMENT DEVELOPMENT INSTITUTE(110111-0776463)

CG BIO CO., LTD.

DAEWOONG PHARMACEUTICAL CO., LTD.(134811-0075342)

DAEWOONG CHEMICAL CO., LTD.(131112-0004827)

DAEWOONG NUTRITIONS CO., LTD.(210111-0013294)

EZMEDICOM CO., LTD.(110111-2063818)

SANWOONG DEVELOPMENT CO., LTD.(110111-0978671)

SANWOONG ENGINEERING CO., LTD.(134811-0034421)

PHARMPAC CO., LTD.(134811-0048307)

PAGE1 CO., LTD.(110111-1771040)

DAEWOONG DEVELOPMENT CO., LTD.(131111-0083649)

IDS&TRUST CO., LTD.(110111-1234006)

BEST SYSTEM CO., LTD.(110111-1639850)

JEJU MOVIELAND CO., LTD.(224111-0014832)

D&P NATURAL MATERIAL RESEARCH INSTITUTE(134511-0102026)

HEALIENCE CO., LTD.(110111-3265778)

BIO AGE CO., LTD.(110111-2458689)

MD WELL INC.(110111-3716854)

HR GROUP CO., LTD.

TRUST CO., LTD.

BIO ALPHA CO., LTD.(110111-1904518)

 

DAEWOONG PHARMACEUTICAL(THAILAND)CO., LTD

DAEWOONG PHARM PHILIPPINES, INCORPORATED

BEIJING DAEWOONG PHARMACEUTICAL R&D CENTER CO., LTD.

 

PT DAEWOONG RIASIMA INDONESIA

(50.0% held by the subject company)

Subsidiary

SACHUN DAEWOONG BIO TECHNOLOGY CO., LTD.(CHINA)

(66.0% held by the subject company)

 

BIO ALPHA CO., LTD.(110111-1904518)

(66.0% held by the subject company)

Corporate Ownership

DAEWOONG CO., LTD.(110111-2857146)

Major Shareholders

DAEWOONG CO., LTD.(110111-2857146)

Cooperative Enterprise

-Insured Company

DONGBU INSURANCE CO., LTD.(110111-0095285)

HANWHA GENERAL INSURANCE CO., LTD.(110111-0006456)

LIG INSURANCE CO., LTD.(110111-0017859)

 

 

Sales by Region (Activity & Markets)

 

Sales/ Unit :Mil KRW

2012

2011

2010

Export

 

 

 

Domestic

 

 

 

Total

 

 

 

The Subject deals with the companies in China, Taiwan, India, Japan, Russia and USA.

 

 

Court Action

 

Case No.

Court

Plaintiff(s)/ Creditor(s)/ Applicant(s)

Defendant(s)/ Debtor(s)/ Respondent(s)

Cause

Amount (KRW)

Status

 

Seoul High Court

The Subject Company

Chang Deuck-Joo

Claim for Compensation from Damages

200,000,000

1st round is proceeding

 

 

News Clipping

 

Not Available


 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.61.58

UK Pound

1

Rs.98.51

Euro

1

Rs.83.49

 

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.